What’s emerging
- Base editing, prime editing, epigenetic editing
- RNA-targeting systems (e.g., Cas13)
- Programmable editing without double-strand breaks
Why it’s promising
- Reduced toxicity and off-target risk
- Clear therapeutic differentiation vs. first-gen CRISPR
IP significance
- Fragmented but fast-moving patent landscape
- Heavy focus on mechanism-specific claims and enablement
- Strong value in delivery + editing method combinations
BioTech IP Review 
Leave a comment